Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.

Histone deacetylase inhibitors (HDACi) are promising epigenetic cancer chemotherapeutics rapidly approaching clinical use. In this study, we tested using in vitro and in vivo models the differential biological effects of a novel HDAC inhibitor [belinostat (PXD101)], in a wide panel of androgen-sensitive and androgen-independent tumor cells. Belinostat significantly increased acetylation of histones H3 and H4. Belinostat potently inhibited the growth of prostate cancer cell lines (IC50 range from 0.5 to 2.5 µM) with cytotoxic activity preferentially against tumor cells. This agent induced G2/M arrest and increased significantly the percentage of apoptosis mainly in androgen-sensitive tumor cells confirming its growth-inhibitory effects. The cell death mechanisms were studied in three different prostate cancer cell lines with different androgen dependence and expression of androgen receptor; LAPC-4 and 22rv1 (androgen-dependent and expressing androgen receptor) and PC3 (androgen-independent not expressing androgen receptor). Belinostat induced the expression of p21 and p27, acetylation of p53 and G2/M arrest associated with Bcl2 and Bcl-Xl downmodulation and significant reduction of survivin, IAPs and Akt/pAkt and increased caspase-8 and -9 expression/activity. Belinostat effectiveness was dependent on the androgen receptor (AR), since the stable transfection of AR greatly increased the efficacy of this HDAC inhibitor. These observations were correlated using in vivo models. We demonstrated that belinostat preferentially resulted in antitumor effect in androgen-dependent tumor cells expressing AR. Our findings provide evidence that belinostat may be a promising anticancer drug for prostate cancer expressing AR, supporting its clinical role in prostate cancer.

[1]  W. Oh,et al.  PC3 is a cell line characteristic of prostatic small cell carcinoma , 2011, The Prostate.

[2]  D. Sherris,et al.  The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. , 2011, Endocrine-related cancer.

[3]  K. Kuroiwa,et al.  Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells , 2011, The Prostate.

[4]  E. Ricevuto,et al.  Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. , 2009, International journal of oncology.

[5]  S. Fulda,et al.  Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8 , 2009, Oncogene.

[6]  H. Prince,et al.  Clinical Studies of Histone Deacetylase Inhibitors , 2009, Clinical Cancer Research.

[7]  L. Borsu,et al.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.

[8]  W. Hahn,et al.  The current state of preclinical prostate cancer animal models , 2008, The Prostate.

[9]  R. Rees,et al.  DNA demethylation and histone deacetylation inhibition co‐operate to re‐express estrogen receptor beta and induce apoptosis in prostate cancer cell‐lines , 2008, The Prostate.

[10]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[11]  D. Qian,et al.  Antitumor activity of the histone deacetylase inhibitor MS‐275 in prostate cancer models , 2007, The Prostate.

[12]  M. Sehested,et al.  The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo , 2007, Cancer Chemotherapy and Pharmacology.

[13]  C. Van Waes,et al.  Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 , 2007, Molecular Cancer Therapeutics.

[14]  M. Sehested,et al.  Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies , 2006, Molecular Cancer Therapeutics.

[15]  M. Carducci,et al.  Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. , 2006, Cancer research.

[16]  B. Aggarwal,et al.  Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-κB Activation* , 2006, Journal of Biological Chemistry.

[17]  Michele Caraglia,et al.  Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo , 2006, Clinical Cancer Research.

[18]  Z. Malik,et al.  In vivo and in vitro antitumor activity of butyroyloxymethyl‐diethyl phosphate (AN‐7), a histone deacetylase inhibitor, in human prostate cancer , 2005, International journal of cancer.

[19]  Hee June Choi,et al.  Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes , 2005, Nature.

[20]  Hing Y Leung,et al.  Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer , 2004, The Prostate.

[21]  D. Neal,et al.  Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. , 2004, European urology.

[22]  D. Leroith,et al.  PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.

[23]  Rakesh Kumar,et al.  Emerging roles of MTA family members in human cancers. , 2003, Seminars in oncology.

[24]  P. Finn,et al.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.

[25]  C. Tepper,et al.  Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.

[26]  Angie Rizzino,et al.  Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. , 2002, Carcinogenesis.

[27]  Lee M Ellis,et al.  Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  R. Dahiya,et al.  Histone deacetylase and DNA methyltransferase in human prostate cancer. , 2001, Biochemical and biophysical research communications.

[29]  Jian Zhang,et al.  Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro , 2001, The Prostate.

[30]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[31]  E. Baldi,et al.  Androgen Receptor Expression in Prostate Carcinoma Cells Suppresses α6β4 Integrin-Mediated Invasive Phenotype. , 2000, Endocrinology.

[32]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[33]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[34]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[35]  W. Oh,et al.  PC 3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma , 2012 .

[36]  W. Gerald,et al.  Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. , 2009, American journal of translational research.

[37]  M. Motta,et al.  Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. , 2003, Oncology research.

[38]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[39]  Bernhard O. Palsson,et al.  Cancer cell lines , 1999 .